Memantin
Memantin je lek iz adamantanske klase lekova za tretiranje Alchajmerove bolesti| koji deluje na glutamatergični sistem putem blokiranja NMDA glutamatnih receptora. On je prvi put sintetisan u kompaniji Eli Lili 1968. Memantin je u prodaju pod imenima Aksura, Akatinol, Namenda, Ebiksa, Abiksa i Memoks. Uprkos dugogodišnjeg istraživanja, postoji malo dokaza da ima uticaja na blagu do umerene Alchajmerovu bolest.[6]
| |||
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| 3,5-dimetiltriciklo[3.3.1.13,7]dekan-1amin ili 3,5-dimetiladamantan-1-amin | |||
| Klinički podaci | |||
| Robne marke | Namenda | ||
| AHFS/Drugs.com | Monografija | ||
| MedlinePlus | a604006 | ||
| Identifikatori | |||
| CAS broj | 19982-08-2 | ||
| ATC kod | N06DX01 | ||
| PubChem[1][2] | 4054 | ||
| DrugBank | DB01043 | ||
| ChemSpider[3] | 3914 | ||
| UNII | W8O17SJF3T 
| ||
| KEGG[4] | D08174
| ||
| ChEMBL[5] | CHEMBL807
| ||
| Hemijski podaci | |||
| Formula | C12H21N | ||
| Mol. masa | 179,3 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakokinetički podaci | |||
| Bioraspoloživost | ~100% | ||
| Metabolizam | Hepatički (<10%) | ||
| Poluvreme eliminacije | 60–100 sati | ||
| Izlučivanje | Renalno | ||
| Farmakoinformacioni podaci | |||
| Licenca | |||
| Trudnoća | ? | ||
| Pravni status | S4 (Au), POM (UK), ℞-only (U.S.) | ||
| Način primene | Oralno | ||
Reference uredi
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Schneider, LS; Dagerman, KS, Higgins, JP, McShane, R (2011). „Lack of evidence for the efficacy of memantine in mild Alzheimer disease.”. Archives of neurology 68 (8): 991–8. PMID 21482915.
Literatura uredi
- Lipton SA (2005). „The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism”. Current Alzheimer research 2 (2): 155–65. DOI:10.2174/1567205053585846. PMID 15974913.
